surmount-1 trial tirzepatide weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled SURPASS to SURMOUNT: The Tirzepatide

Our latest presentations unpack how food and lifestyle can enhance outcomes and reduce side effects, with practical strategies backed by clinical evidence

Remember, one indulgent meal wont derail your progress, but consistently overindulging can hinder your weight loss efforts

The formulation of oral semaglutide was achieved by coupling semaglutide to sodium- N -[8-(2-hydroxybezoyl)-amino]caprylate (SNAC), which functions as an absorption enhancer

N-Acetylcysteine (NAC) 100mg- can help reduce the appearance of blemishes

Clinical studies have shown significant weight loss in individuals using semaglutide, particularly in those who are obese or have a high BMI and are at risk for conditions such as diabetes or heart disease

Nearly 8 in 10 companies reported expensive weight loss medications were driving up their company's costs